Pulmatrix cites stockholder nod, S-4 effectiveness in Eos SENOLYTIX merger update
Pulmatrix says the merger agreement targets a November 2026 close, with the company separately saying it expects completion by year end, subject to Nasdaq and other conditions.
Pulmatrix reported third-quarter 2026 results on November 17, 2026 alongside an update on its pending merger with Eos SENOLYTIX, Inc., a privately held company developing gerotherapeutic peptides. Interim CEO Peter Ludlum said the quarter's focus was advancing the proposed merger with Eos SENOLYTIX, and the company has obtained SEC effectiveness on its Form S-4 registration statement along with stockholder approval for the merger.1 He added that the company anticipates closing the proposed merger by the end of the year.1
Separately, the merger agreement itself states that the deal is currently anticipated to close in November 2026, subject to Nasdaq's approval of listing the shares to be issued, completion of the reverse stock split stockholders approved on October 26, 2026, and other customary closing conditions.1 The S-4 registration statement was initially filed July 9, 2026 and declared effective September 25, 2026.1
On the pipeline side, Pulmatrix said its partner Cipla has been approved by India's Central Drug Standard Control Organization to proceed with a Phase 3 trial of PUR1900, the inhaled itraconazole candidate, after completing a Phase 2 study in India with positive results; Cipla currently expects the Phase 3 to begin in 2026.1 For PUR3100, the inhaled migraine candidate, the FDA has accepted the IND application and issued a study-may-proceed letter for a Phase 2 trial.1 The company noted that R&D spending was under $0.1 million for the quarter, as all clinical development remains on hold while Pulmatrix works to license or monetize its clinical assets.1
On cash, Pulmatrix reported total cash and equivalents of $1.4 million as of September 30, 2026, plus $0.7 million in restricted cash tied to the merger, compared with $4.1 million at the end of 2025.1 The company said its current cash position, based on operational efficiencies and spending prioritization, is sufficient to fund operations at least through the anticipated closing of the Eos merger.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.